At a Glance
Quickcomparison
Dose Range
Angiotensin (1-7)
0.5-1 mcg/kg–5-10 mcg/kg mcg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
As directed by healthcare provider
Subcutaneous injection
Cycle Length
Ongoing/indefinite
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Moderate human trials (Phase 1-2)
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Heart Health & Protection
Blood Pressure Balance
Anti-Inflammatory Support
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C41H62N12O11
Molecular Weight
899.02 g/mol
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS Number
25016-41-7
C62H98N16O22
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
standard
100 mcg/kg
Once daily after each chemotherapy session
Up to 6 chemotherapy cycles
In a cancer trial, this dose was injected under the skin after chemo to help protect platelet counts. A higher 300 mcg/kg dose was also tested but did not work better. [4]
0.5 mg/kg
Up to 10 days
In a COVID-19 study, the lab-made form (called TXA-127) was given as a daily drip into a vein. No serious drug-related side effects were seen. [5]
starting
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily
Commonly used range for tissue and tendon recovery in research practice [1][3].
advanced
500 mcg
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Applications
Bestsuited for
Cardiovascular health and heart protection
Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Blood pressure management and hypertension
Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from heart-related conditions
Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory support
Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Hypotension (Low Blood Pressure)
Dizziness or Lightheadedness
Injection Site Reactions
Headache
Serious
Hyperkalemia (High Potassium)
Injection site redness
Mild nausea
Dizziness
Uncommon
Fatigue
Hot/cold sensations
Allergic reaction
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans.
Contraindications
xSevere hypotension or uncontrolled low blood pressure
xAcute myocardial infarction in early stages
xConcurrent use with certain ACE inhibitors without medical supervision
xPregnancy and breastfeeding (insufficient safety data)
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose Angiotensin (1-7) if...
Cardiovascular health and heart protection
Blood pressure management and hypertension
Recovery from heart-related conditions
Anti-inflammatory support
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health